Cardiawave was created at the end of 2014 as a result of a partnership of over 6 years between the academic laboratories Physics for Medicine Paris (INSERM/CNRS/ESPCI/PSL) and Langevin Institute (CNRS/INSERM/ESPCI), world leaders in ultrasound imaging and therapy, and the Georges Pompidou European Hospital (HEGP), a leader in the field of valve disease and cardiac ultrasound imaging.
Based at the business incubator of Paris Biotech Santé in Cochin and member of the national research consortium RHU Stop-AS and of the competitiveness cluster MEDICEN Paris Région, Cardiawave employs 26 people and has secured over €22M in funding since its inception.
With a quality management system that is EN ISO 13485:2016 certified since 2019, Cardiawave has developed Valvosoft®, a non-invasive ultrasound therapy medical investigational device for the treatment of calcific aortic stenosis (CAS), the most prevalent heart valve disease in adults and one of the most common causes of cardiovascular mortality worldwide. Cardiawave’s mission is to improve the quality of patient care by offering medical devices for non-invasive therapies.
Early 2019, Cardiawave was granted approval to perform a first-in-human feasibility clinical study (FIH‑I) in France and in the Netherlands enrolling 10 patients. Another study (FIH-II) has been approved in Serbia and started at the end of 2019. In 2020, Cardiawave obtained approval for an extension of its FIH-I increasing the study population up to 30 patients. This study extension is on-going.
A Research Letter presenting the preliminary results of the FIH-I has been published in Circulation on January 25, 2021.


SCIENTIFIC PUBLICATIONS
Pulsed Cavitational Ultrasound Softening: a new non-invasive therapeutic approach of calcified bioprosthetic valve stenosis. – Journal of the American College of Cardiology Basic to Translational Science, August 2017.
Villemain O, Robin J, Bel A, Kwiecinski W, Bruneval P, Arnal B, Rémond M, Tanter M, Messas E, Pernot M.
2(4):372-383. DOI: 10.1016/j.jacbts.2017.03.012.
Feasibility and Safety of Non-Invasive Ultrasound Therapy (NIUT) on Porcine Aortic Valve. – Physics in Medicine & Biology, July 2020.
Messas E. et al
DOI 10.1088/1361-6560/aba6d3
Feasibility and Performance of Noninvasive Ultrasound Therapy in Patients With Severe Symptomatic Aortic Valve Stenosis: A First-in-Human Study – Circulation by American Heart Association, January 2021.
Messas E, IJsselmuiden A, Goudot G, Vlieger S, Zarka S, Puymirat E, Cholley B, Spaulding C, Hagège A, Marijon E, Tanter M, Bertrand B, Rémond M, Penot R, Ren B, Den Heijer P, Pernot M, and Spaargaren R
143:00-00. DOI: 10.1161/CIRCULATIONAHA.120.050672
Awards & Honours
2020 Tech Tour finalists
Tech Tour
2019 “Best Fit to the US market”, pitch contest in Boston
Care Tour
2019 Prize-winner of the International Symposium on Therapeutic Ultrasound: Student Award
ISTU / Barcelona
2018 Prize-winner of Gallien MedStart’Up, in the category: Best Collaboration with Academia Leading to a Breakthrough Solution, partnering with Mount Sinai Medical Center New York
USA
2018 Prize-winner of SME Instrument, Phase 2
European Union
2017 Prize-winner of Worldwide Innovation Contest (CMI), 3rd phase
French government / BPI France
2015 Prize-winner of Worldwide Innovation Contest (CMI), 2nd phase
French government / BPI France
2015 Prize winner of Fondation pour l’Innovation Thérapeutique Béatrice Denys
Turenne Capital (French Investment Fund)
2014 Prize-winner of Worldwide Innovation Contest (CMI), 1st phase
French government / BPI France
2014 Prize-winner of the French National Contest for Innovative Technologies Companies
French government / BPI France
Management




Board of Directors






Scientific Advisory Board








TEAM























